X Pharmaceuticals, Inc. has been manufacturing the antibiotic ointment Marvelopis, which is covered by a patent expiring in the year 2020. In January 2019, the company filed an application for a new patent for Disilopis, which, although constituting the same substance as Marvelopis, is no longer treated as an antibiotic but is targeted and marketed for a new use, i.e., skin whitening.
(a) What are the three (3) requisites of patentability under the Intellectual Property Code? (3%)
(b) Should X Pharmaceuticals, Inc.’s patent application for Disilopis be granted? Explain. (2%)
Suggested answer only. Not an official answer and not legal advice.
(a) The three requisites of patentability are novelty, inventive step, and industrial applicability. (b) No, X Pharmaceuticals, Inc.'s patent application for Disilopis should not be granted. Under Sections 21, 22, and 26.2 of the Intellectual Property Code (R.A. No. 8293, as
Unlock the full Commercial Law answers365 days of full access. GCash, Maya and card accepted.
This is not an official scoring system and carries no weight with the Supreme Court or any bar review provider. It measures how much of the suggested answer's wording your response covers, not whether your reasoning is correct. For practice only.
Quick check
Under Section 21 of the Intellectual Property Code, what are the three essential requisites for an invention to be patentable?
Section 21 provides that an invention is patentable if it is new, involves an inventive step, and is industrially applicable.
Under Republic Act Number 9502 (Cheaper Medicines Act), what is the rule regarding the discovery of a new use for a known drug substance?
R.A. 9502 explicitly excludes the mere discovery of a new use for a known substance from patentability.
What practice does Section 22 of the Intellectual Property Code seek to prevent by excluding new uses of known substances from patentability?
The statutory exclusion prevents pharmaceutical evergreening by prohibiting new patents over known substances.
Why should X Pharmaceuticals, Inc.'s patent application for Disilopis be denied by the Intellectual Property Office?
Choices available with full access.
Which statute amended the Intellectual Property Code to restrict patentability of new uses for known pharmaceutical substances in the Philippines?
Choices available with full access.
Learn more about these topics
1. Patentability Requisites
Under Section 21 of the Intellectual Property Code of the Philippines (Republic Act Number 8293), any technical solution of a problem in any field of human activity which is new, involves an inventive step, and is industrially applicable is patentable. Novelty requires that an invention does not form part of the prior art. An inventive step exists if, having regard to the prior art, the invention is not obvious to a person skilled in the art. Industrial applicability requires that the invention can be produced or used in any industry.
2. Non-Patentable Discoveries
Under Section 22.1 of Republic Act Number 8293, as amended by the Cheaper Medicines Act (Republic Act Number 9502), the mere discovery of a new form or new property of a known substance which does not result in the enhancement of the known efficacy of that substance, or the mere discovery of any new use for a known substance, is non-patentable. This statutory prohibition prevents pharmaceutical companies from engaging in evergreening, a practice where patent monopolies are artificially extended by applying for new patents over known active chemical substances based solely on newly discovered medical uses.
3. Pharmaceutical Evergreening Prohibition
Evergreening refers to the practice of obtaining multiple patents over a single pharmaceutical compound by filing subsequent applications for minor modifications, new formulations, or new therapeutic uses. Under Republic Act Number 9502, Philippine patent law strictly excludes new uses of existing active drug substances from patent protection to ensure public access to affordable generic medicines. Consequently, when a pharmaceutical entity attempts to patent a known active substance merely by rebranding or marketing it for a different therapeutic application, the patent application must be denied for lack of novelty and inventive step.